New Community and Sociohealth Challenges Arising from the Early Diagnosis of Mild Cognitive Impairment (MCI)

Author:

López Carolina1,Altuna Miren12ORCID

Affiliation:

1. Fundación CITA-Alzheimer Fundazioa, 20009 Gipuzkoa, Spain

2. Osakidetza, Organización Sanitaria Integrada (OSI), 20690 Gipuzkoa, Spain

Abstract

Population aging increases the risk of developing neurodegenerative diseases that cause cognitive impairment. Advances in clinical practice and greater social awareness of the importance of cognitive impairment have led to an increase in the number of people with early diagnosis, predementia. Increasing access to biomarkers to assess whether Alzheimer’s disease (AD) is the underlying cause of mild cognitive impairment (MCI) has undoubted clinical benefits (access to potentially disease-modifying treatments, among others) but is also responsible for new social–health care challenges. Understanding the psychosocial impact of a diagnosis of MCI due to AD or another neurodegenerative disease is essential to create future strategies to reduce the emotional overload of patients, their risk of discrimination and stigmatization, and to favor their social inclusion. We present a narrative review of the diagnostic process of mild cognitive impairment in clinical practice, with a holistic person-centered approach, and discuss the implications of such diagnosis (benefits and risks) and strategies on how to address them.

Publisher

MDPI AG

Subject

Medicine (miscellaneous)

Reference72 articles.

1. European Academy of Neurology/European Alzheimer’s Disease Consortium Position Statement on Diagnostic Disclosure, Biomarker Counseling, and Management of Patients with Mild Cognitive Impairment;Frederiksen;Eur. J. Neurol.,2021

2. Worldwide Prevalence of Mild Cognitive Impairment among Community Dwellers Aged 50 Years and Older: A Meta-Analysis and Systematic Review of Epidemiology Studies;Bai;Age Ageing,2022

3. Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project;Manly;JAMA Neurol.,2022

4. Aducanumab: Evidence from Clinical Trial Data and Controversies;Tampi;Drugs Context,2021

5. Lecanemab in Early Alzheimer’s Disease;Swanson;N. Engl. J. Med.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3